TickerKhojComparison · NSE · data 2026-11-03
Dr. Lal PathLabs Limited vs Thyrocare Technologies Ltd
In plain words
Size: Dr. Lal PathLabs Limited is about 4.2 times the market value of Thyrocare Technologies Ltd.
Return on equity: Thyrocare Technologies Ltd 28.8% vs Dr. Lal PathLabs Limited 21.6%.
Profit growth over 3 years: Thyrocare Technologies Ltd 36.2% a year vs Dr. Lal PathLabs Limited 28.3% a year.
Debt to equity: Thyrocare Technologies Ltd 0.09 vs Dr. Lal PathLabs Limited 0.08.
Differences in the numbers, not a recommendation of either stock.
Side by side
19 metrics shown
| LALPATHLAB | THYROCARE | |
|---|---|---|
| Price | ₹1,925.7 | ₹482.9 |
| Market cap | ₹31,681 cr | ₹7,593 cr |
| P/E | 59.4 | 54 |
| P/B | — | 13.9 |
| ROE | 21.6% | 28.8% |
| ROCE | 25.3% | 34.2% |
| Debt / equity | 0.08 | 0.09 |
| Operating margin | 23.0% | 25.6% |
| Dividend yield | 0.85% | 1.96% |
| Sales growth, 3 years (yearly) | 11.1% | 16.3% |
| Profit growth, 3 years (yearly) | 28.3% | 36.2% |
| 1-year return | 22.1% | 3.1% |
| Revenue, last 12 months | ₹2,891 cr | ₹930 cr |
| Net profit, last 12 months | ₹542 cr | ₹144 cr |
| Latest quarter | Jun 2026 | Sept 2026 |
| Quarter net profit | ₹170 cr | ₹16 cr |
| Quarter profit vs a year earlier | +28.0% | -66.9% |
| Promoter holding | 52.93% | 51.02% |
| Health check | Strong (8/10) | Strong (6.8/10) |
Common questions
Which has a higher P/E, Dr. Lal PathLabs Limited or Thyrocare Technologies Ltd?
Dr. Lal PathLabs Limited trades at the higher P/E (59.4 against 54). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Thyrocare Technologies Ltd (28.8% against 21.6%).
Which carries more debt?
Thyrocare Technologies Ltd has the higher debt-to-equity ratio (0.09 against 0.08).